Since our previous study identified an antitumor immune stimulatory effect caused by LSD1 inhibition-induced type I interferon activation in poorly immunogenic tumor models such as B16/F10 and D4m.3A31, we next sought to determine whether this anti-tumor effect of GSK2879552 came from LSD1 inhibition in tumor or immune cells. Here, KDM1A is linked to neoplasm.